Biotech Values

[DewDiligence]

AERI -21%/AH on purportedly positive phase-2b in dry-eye:

https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-novel-dry-200100387.html

Of particular note, we are excited at the number of symptom endpoints which demonstrated statistical significance given the importance of this for patients suffering from dry eye disease. While we did not achieve statistical significance at our pre-determined primary endpoints at Day 28, as a reminder, this is a Phase 2b study where selecting primary endpoints are not required [emphasis added].

LOL